Cancer Prevention Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cancer Prevention Pharmaceuticals, Inc.
Gilead Awaits EMA Verdict On Trodelvy As It Whizzes Through EU Review
Sponsors of six new products, including a first-in-class treatment for unresectable locally advanced or metastatic triple-negative breast cancer, will find out this week if their products are on course to be approved for use in the EU. Also, two sponsors might be asked to address last-minute questions about their drugs.
BeiGene’s Brukinsa Among Nine Drugs To Win EU Marketing Thumbs Up
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
Sanofi Genzyme’s Treatment For Pompe Disease On Track For EU Approval
EU reviewers have recommended marketing approval for two new medicines, but have turned down another product.
Kyowa Awaits EU Decision On Drug For Treating Parkinson’s ‘Off’ Time
The European Medicines Agency is meeting this week to decide whether two new drugs, including one that enhances anti-parkinsonian activity, should be approved for use in the EU. Also, the sponsor of a treatment for the rare degenerative muscle disorder, Pompe disease, is expected to attend an oral explanation meeting to address last-minute questions.
- Other Names / Subsidiaries
- Panbela Therapeutics, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.